NOTRELOAD AI
  • NOTRELOAD AI
  • Invest ↗
  • myNOTRELOAD (BETA)
  • XY Feed
  • 24-HOUR Pass →
Sign in Subscribe

Akebia Therapeutics Halts Proposed Anemia Trial After FDA Feedback

Akebia Therapeutics will not start its planned trial for Vafseo anemia treatment in non-dialysis kidney disease patients after the FDA requested a larger, costlier study.

Akebia Therapeutics Halts Proposed Anemia Trial After FDA Feedback
Credit: Akebia Therapeutics
Already have an account? Sign in.
Featured/ 10/28/2025 · 6:05 PM
AKBA
/ Don’t stop at just one post.

Related↓

Q32 Bio Sells Drug Asset to Akebia Therapeutics
12/01/2025 · 7:35 AM

Q32 Bio Sells Drug Asset to Akebia Therapeutics

Q32 Bio sells complement inhibitor ADX-097 to Akebia for $12M upfront plus milestone payments up to $592M, extending cash runway to mid-2027 while focusing on alopecia treatment.

/ Subscriber only
/ Read more

Feed↓

Tempus AI Shares Rise on New Angiosarcoma Research Collaboration
06/25/2026 · 11:29 AM

Tempus AI Shares Rise on New Angiosarcoma Research Collaboration

Tempus AI announces research collaboration with Angiosarcoma Awareness, analyzing ~600 patient records with paired DNA/RNA data to accelerate rare cancer insights.

/ Subscriber only
OVHcloud Accelerates Growth in Q3 but Shares Tumble on CapEx Concerns
06/25/2026 · 8:20 AM

OVHcloud Accelerates Growth in Q3 but Shares Tumble on CapEx Concerns

Public cloud revenue jumped 20% at OVHcloud in Q3, driving overall growth. However, shares dropped on concerns over higher capital spending and cautious full-year outlook.

/ Subscriber only
BlackBerry Raises Full-Year Revenue Guidance After Strong Q1 Beat
Featured/ 06/25/2026 · 7:42 AM

BlackBerry Raises Full-Year Revenue Guidance After Strong Q1 Beat

The company beat estimates and raised its full-year revenue guidance to $594–621 million, driven by QNX and Secure Communications growth.

/ Subscriber only
  • UP↑
  • Terms/Privacy
  • Sign up
  • Sign in
  • Discord
  • X
  • Bluesky
  • Telegram
  • Reach out →
  • Invest ↗
  • NOTRELOAD AI
DON'T FALL BEHIND. ©2025
Email address Subscribe